Patricia Chauke1, Mmampedi Huma1, Sphiwe Madiba1. 1. Department of Public Health, School of Health Care Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa.
Abstract
INTRODUCTION: South Africa adopted and implemented the Universal Test and Treat (UTT) strategy for HIV since 2016. However, the care outcomes for patients initiated antiretroviral therapy (ART) through the UTT strategy have not been established. We determined the rate of lost to follow up (LTFU) and associated factors in patients who were initiated on ART through the UTT and the pre-ART strategy at 12 months post ART initiation. METHODS: this retrospective study analyzed the records of a cohort of patients at 12 months post the initiation of ART. We extracted data from the TIER.Net electronic database of selected facilities in a sub-district in Gauteng Province, South Africa. Factors associated with LFTU at 12 months of ART were assessed and logistic regression performed to identify predictors of LFTU. RESULTS: records of 367 patients were evaluated, and 54% were initiated ART through the UTT strategy. The mean age was 36.3 years, mean CD4 cell count at ART initiation was 341 cells/mm3, and 25% were initiated at CD4 cell count above 500 cells/mm3. LTFU at 12 months was 28%, 50% were LFTU within six months, and 28% within three months of ART. LFTU in the UTT cohort was higher than in the pre-ART cohort, patients initiated through UTT were twice more likely to be LTFU (AOR = 1.84, CI: 1.13-3.00) than pre-ART patients. CONCLUSION: the rate of LTFU at 12 months of ART was 28%, which indicate that the retention in care rate (60%) falls far short of the triple 90 targets required for viral suppression. Copyright: Patricia Chauke et al.
INTRODUCTION: South Africa adopted and implemented the Universal Test and Treat (UTT) strategy for HIV since 2016. However, the care outcomes for patients initiated antiretroviral therapy (ART) through the UTT strategy have not been established. We determined the rate of lost to follow up (LTFU) and associated factors in patients who were initiated on ART through the UTT and the pre-ART strategy at 12 months post ART initiation. METHODS: this retrospective study analyzed the records of a cohort of patients at 12 months post the initiation of ART. We extracted data from the TIER.Net electronic database of selected facilities in a sub-district in Gauteng Province, South Africa. Factors associated with LFTU at 12 months of ART were assessed and logistic regression performed to identify predictors of LFTU. RESULTS: records of 367 patients were evaluated, and 54% were initiated ART through the UTT strategy. The mean age was 36.3 years, mean CD4 cell count at ART initiation was 341 cells/mm3, and 25% were initiated at CD4 cell count above 500 cells/mm3. LTFU at 12 months was 28%, 50% were LFTU within six months, and 28% within three months of ART. LFTU in the UTT cohort was higher than in the pre-ART cohort, patients initiated through UTT were twice more likely to be LTFU (AOR = 1.84, CI: 1.13-3.00) than pre-ART patients. CONCLUSION: the rate of LTFU at 12 months of ART was 28%, which indicate that the retention in care rate (60%) falls far short of the triple 90 targets required for viral suppression. Copyright: Patricia Chauke et al.
Entities:
Keywords:
ART; HIV; South Africa; lost to follow up; retention in care; universal test and treat
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Anna Grimsrud; Morna Cornell; Michael Schomaker; Matthew P Fox; Catherine Orrell; Hans Prozesky; Kathryn Stinson; Frank Tanser; Matthias Egger; Landon Myer Journal: J Epidemiol Community Health Date: 2015-12-23 Impact factor: 3.710
Authors: Olivier Koole; Sharon Tsui; Fred Wabwire-Mangen; Gideon Kwesigabo; Joris Menten; Modest Mulenga; Andrew Auld; Simon Agolory; Ya Diul Mukadi; Robert Colebunders; David R Bangsberg; Eric van Praag; Kwasi Torpey; Seymour Williams; Jonathan Kaplan; Aaron Zee; Julie Denison Journal: Trop Med Int Health Date: 2014-09-17 Impact factor: 2.622
Authors: Benjamin H Chi; Constantin T Yiannoutsos; Andrew O Westfall; Jamie E Newman; Jialun Zhou; Carina Cesar; Martin W G Brinkhof; Albert Mwango; Eric Balestre; Gabriela Carriquiry; Thira Sirisanthana; Henri Mukumbi; Jeffrey N Martin; Anna Grimsrud; Melanie Bacon; Rodolphe Thiebaut Journal: PLoS Med Date: 2011-10-25 Impact factor: 11.069
Authors: Legese A Mekuria; Jan M Prins; Alemayehu W Yalew; Mirjam A G Sprangers; Pythia T Nieuwkerk Journal: PLoS One Date: 2015-06-26 Impact factor: 3.240
Authors: Morna Cornell; Leigh F Johnson; Robin Wood; Frank Tanser; Matthew P Fox; Hans Prozesky; Michael Schomaker; Matthias Egger; Mary-Ann Davies; Andrew Boulle Journal: J Int AIDS Soc Date: 2017-09-25 Impact factor: 5.396
Authors: Jan A C Hontelez; Mark N Lurie; Till Bärnighausen; Roel Bakker; Rob Baltussen; Frank Tanser; Timothy B Hallett; Marie-Louise Newell; Sake J de Vlas Journal: PLoS Med Date: 2013-10-22 Impact factor: 11.069
Authors: Mhairi Maskew; Alana T Brennan; Willem D F Venter; Matthew P Fox; Lungisile Vezi; Sydney Rosen Journal: J Int AIDS Soc Date: 2021-10 Impact factor: 5.396
Authors: Mohammed Limbada; David Macleod; Vasty Situmbeko; Ellen Muhau; Osborn Shibwela; Bwalya Chiti; Sian Floyd; Albertus J Schaap; Richard Hayes; Sarah Fidler; Helen Ayles Journal: Lancet HIV Date: 2021-11-26 Impact factor: 16.070